Open AccessUse of First-Line PARP Inhibitors in Ovarian Cancer
Author(s) -
Ursula Hasler-Strub
Publication year - 2019
Publication title -
healthbook times. oncology hematology
Language(s) - English
Resource type - Journals
eISSN - 2673-2106
pISSN - 2673-2092
DOI - 10.36000/hbt.oh.2019.02.006
Subject(s) - veliparib , olaparib , bevacizumab , ovarian cancer , oncology , medicine , chemotherapy , front line , parp inhibitor , poly adp ribose polymerase , cancer , polymerase , biology , biochemistry , gene , political science , law
Platinum-based chemotherapy regimens are the mainstay of advanced ovarian cancer treatment. However, up to 85% of the patients experience recurrence under these settings. To fill this gap, novel front-line treatment strategies have been established, leading to unprecedented clinical benefits. For example, first-line bevacizumab, an anti-angiogenic agent, plus chemotherapy followed by bevacizumab maintenance, has emerged as a new standard of care for newly diagnosed high risk ovarian cancer patients. This was based on the results of the phase III GOG 0218 and ICON-7 trials. More recently, poly(ADP)-ribose polymerase (PARP) inhibitors, including niraparib, olaparib and veliparib, have offered a new treatment option as part of the front-line treatment in ovarian cancer. Here we provide an overview of three recent studies that may lead to a paradigm shift in the first-line treatment for advanced ovarian cancer.